molecular glues – Talk Bio

Building the Next Generation of Biologics: Inside the Future of Protein Engineering

5 days ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug Conjugates, cryo-EM, generative biology, high-throughput protein production, manufacturability, mini-proteins, molecular glues, next-generation biologics, PROTACs, protein degraders, protein design, Protein Engineering, Structural Biology

next-generation biologics; protein engineering; bispecific antibodies; antibody-drug conjugates (ADCs); protein degraders; PROTACs; molecular glues; mini-proteins; AI in protein design; manufacturability; structural biology; cryo-EM; high-throughput protein production; generative biology

Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking the big next step after AlphaFold 3

9 months ago talkbio0Tagged molecular glues, Neo-1, Study models

Neo-1, Study models, molecular glues

Biogen Expands Portfolio with Neomorph Molecular Glues Deal Worth Up to $1.45 Billion

1 year ago talkbio0Tagged Biogen, biotech, deal, molecular glues, Neomorph, pharmaceutical acquisition

Biogen, Neomorph, Molecular Glues, Biotech Deal, Pharmaceutical Acquisition

AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront

1 year ago talkbio0Tagged AstraZeneca, Cancer Therapeutic Procedure, Epidermal Growth Factor Receptor, licensing agreement, milestone payments, molecular glues, Neoplasms, Pinetree, Protein Degradation, Metabolic, protein degrader, royalties

AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment